Published in Physician Law Weekly, October 27th, 2004
Immunomedics filed suit on February 17, 2000 against Cytogen and Bard, alleging that use of Cytogen's ProstaScint product infringed U.S. Patent No. 4,460,559, which claims a method for detecting and localizing tumors. The settlement with Immunomedics is on behalf of Cytogen and Bard.
Founded in 1980, Cytogen Corporation of Princeton, New Jersey, is a product-driven, oncology-focused biopharmaceutical company that develops and commercializes a balanced portfolio...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly